0001567619-18-008589.txt : 20181226 0001567619-18-008589.hdr.sgml : 20181226 20181226163504 ACCESSION NUMBER: 0001567619-18-008589 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181224 FILED AS OF DATE: 20181226 DATE AS OF CHANGE: 20181226 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gurney Austin CENTRAL INDEX KEY: 0001553353 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35993 FILM NUMBER: 181252949 MAIL ADDRESS: STREET 1: C/O ONCOMED PHARMACEUTICALS, INC. STREET 2: 800 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OncoMed Pharmaceuticals Inc CENTRAL INDEX KEY: 0001302573 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 383572512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 800 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-995-8200 MAIL ADDRESS: STREET 1: 800 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 doc1.xml FORM 4 X0306 4 2018-12-24 1 0001302573 OncoMed Pharmaceuticals Inc OMED 0001553353 Gurney Austin C/O ONCOMED PHARMACEUTICALS, INC. 800 CHESAPEAKE DRIVE REDWOOD CITY CA 94063 0 1 0 0 See Remarks Common Stock 2018-12-24 4 S 0 11117 0.5999 D 66807 D Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit ("RSU") award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes. This transaction was executed in multiple trades in prices ranging from $0.5601 to $0.6, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Chief Scientific Officer, Senior Vice President, Research /s/ Alicia J. Hager, Attorney-in-Fact for Austin Gurney 2018-12-26